Lipum and NorthX Biologics enter into new strategic manufacturing alliance

18 April 2024

Lipum AB (Publ), a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases today announces that
it has entered into a manufacturing alliance with NorthX Biologics AB, a Contract Development and Manufacturing Organisation (CDMO).

Under this agreement NorthX will manufacture Lipum´s lead asset, SOL-116, a humanized antibody, for use in a phase II clinical trial. SOL-116 is transferred from the current manufacturer to NorthX which will lead to cost and time savings with high quality.

Ola Sandborgh, CEO of Lipum said “We are delighted to be partnering with NorthX and it represents an important step as we move forward into our phase II trial. NorthX´s capabilities are a great fit and provide a cost effective one-stop-shop for both drug substance and sterile fill finish drug product. I am very much looking forward to the collaboration and bringing this therapy a step closer to patients”. Janet Hoogstraate, CEO of NorthX Biologics added “We are excited to be working on SOL-116 and look forward to adding our expertise and experience in the GMP manufacture of advanced biologics to the ultimate benefit of patients”.

Press Release Download here

For more information

About NorthX Biologics AB

NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.

For more news, follow us on LinkedIn